Guidelines of the Spanish Society of Cardiology. Cardiac transplantation and heart-lung transplantation;Guias de actuacion clinica de la Sociedad Espanola de Cardiologia. Trasplante cardiaco y de corazon-pulmones

Revista Espanola de Cardiologia

Volumn 52, Issue 10, 1999, Pages 821-839

  Alonso Pulpón, Luis ^b   Almenar, Luis ^b   Crespo, María G ^b   Silva, Lorenzo ^b   Segovia, Javier ^b   Manito, Nicolás ^b   Cuenca, José Joaquín ^b   Juffé, Alberto ^b   Vallés, Federico ^b  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b NONE

Author keywords

Guidelines; Heart transplantation; Heart lung transplantation

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID;

CARDIOLOGY; CLINICAL PRACTICE; GRAFT REJECTION; HEART LUNG TRANSPLANTATION; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MEDICAL SOCIETY; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; REVIEW; SURVIVAL; ARTICLE; BIOPSY; DONOR; LEGAL ASPECT; PATHOLOGY; PATIENT SELECTION; SPAIN; STANDARD; UTILIZATION REVIEW;

BIOPSY; CARDIOLOGY; GRAFT REJECTION; HEART TRANSPLANTATION; HEART-LUNG TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PATIENT SELECTION; SPAIN; TISSUE DONORS;

EID: 0032740165     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0300-8932(99)75010-4     Document Type: Review

References (75)

1. Almenar L, en representación de los Grupos Españoles de Trasplante Cardíaco Registro Nacional de Trasplante Cardíaco. IX Informe Oficial (1984-1997). Rev Esp Cardiol 1999; 52: 153-159.
2. Hosenpud JD, Bennett LE, Keck BM, Fiol B, Boucek MM, Novick RJ. The Registry of the International Society for Heart and Lung Transplantation: Fifteenth Official Report - 1998. J Heart Lung Transplantation 1998; 17: 656-668.
3. Hunt, SA. Current status of cardiac transplantation. JAMA 1998; 280: 1.692-1.698.
4. Concha-Ruiz M, Arizón del Prado J, Crespo-Leiro M, Llorens-León R. Trasplante cardíaco. Conferencia Consenso Nacional 1996. Barcelona: J Uriach y Cía. S.A., 1996; 144.
5. Costanzo M. Selection and treatment of candidates for heart transplantation. Sem Thorac Cardiovase Surg 1996; 8: 113-125.
6. Miller L, Kubo S, Young J, Stevenson L, Loh E, Costanzo M. Report of the Consensus Conference on candidate selection for heart transplantation. 1993. J Heart Lung Transplant 1995; 14: 562-571.
7. Miller LW. Listing criteria for cardiac transplantation. Results of an American Society of Transplant Physicians-National Institutes of Health Conference. Transplantation 1998; 66: 947-951.
8. Costanzo MR, Augustine S, Bourge R, Bristow M, O'Connell JB, Driscoll D et al. Selection and treatment of candidates for heart transplantation. A statement for health professionals from the Committee on Heart Failure and Cardiac Transplantation Council on Clinical Cardiology, American Heart Association. Circulation 1995; 92: 3.593-3.612.
9. Hawkins PN, Pepys MB. Role of heart transplantation in systemic amyloidosis. J Heart Lung Transplant 1996; 15: 321-322.
10. Hosenpud JD, Uretsky B, Griffith BP, O'Connell JB, Olivari MT, Valantine HA. Successful intermediate-term outcome for patients with cardiac amyloidosis undergoing heart transplantation: results of a multicenter survey. J Heart Lung Transplant 1990; 9: 346-350.
11. Sumeray MS, Murday AJ. Pulmonary amyloidosis occurring after heart transplantation for amyloid heart disease. J Heart Lung Transplant 1995; 14: 402-403.
12. Barbers RG. Role of transplantation (lung, liver and heart) in sarcoidosis. Clin Chest Med 1997; 18: 865-874.
13. Armitage JM, Kormos RL, Griffith BP, Fricker FJ, Hardesty RL. Heart transplantation in patients with malignant disease. J Heart Lung Transplant 1990; 9: 627-629.
14. Batabasi G, Massetti M, Agostini D, Galateau F, Salux E, Nataf P et al. Recurrent left-sided heart leiomyosarcoma: should heart transplantation be legitimated? J Heart Transplant 1998; 17: 1.133-1.138.
15. Crespo MG, Pulpón LA, Pradas G, Serrano S, Segovia J, Vegazo I et al. Heart transplantation for cardiac angiosarcoma: should its indication be questioned? J Heart Lung Transplant 1993; 12: 527-530.
16. Baay P, Karwande SV, Kushner JP, Olsen S, Renlund DG. Successful treatment of cardiac angiosarcoma with combined modality therapy. J Heart Lung Transplant 1994; 13: 391-394.
17. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH Jr, Wilson JR. Value of peak exercise oxigen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991; 83: 3: 778.
18. Kshettry VR, Bolman RM. Transplantation of the heart and both lungs. Indications, selection and evaluation. En: Cooper DKC, Miller LW, Patterson DA. editores. The transplantation and replacement of thoracic organs. Dordretch: Kluwer Academic Publishers, 1996; 605-608.
19. Chamorro C. Evaluación del donante de órganos. Madrid: Clínica Puerta de Hierro, 1998.
20. Baldwin JC, Anderson JL, Boucek MM, Bristow MR, Jennings B. Ritsch ME Jr et al. Task face II: Donor guidelines. Twenty-fourth Bethesda Conference on Cardiac Transplantation. J Am Coll Cardiol 1993; 22: 15-20.
21. Schuler S. Warnecke H, Loebe M, Fleck E, Hetzer R. Extended donor age in cardiac transplantation. Circulation 1989; 80: 133-139.
22. Constanzo-Nordin MR, Liao YL, Grusk BB, O'Sullivan EJ, Cooper RS, Johnson MR et al. Oversizing of donor hearts: beneficial or detrimental? J Heart Lung Transplant 1991; 10: 717-730.
23. Fernández Lucas M, Matesanz R. Documento Internacional de Consenso. Madrid: ONT, 1996.
24. Gottesdiener KM. Transplanted Infections: donor -to-host transmission with the allograft. Ann Intern Med 1989; 110: 1.001-1016.
25. Eastlund T. Infections disease transmision through cell, tissue, and organ transplantation: reducing the rish through donor selection. Cell Transplant 1995; 4: 445-447.
26. Burgess BI, Roberts P, Boguski J, Lovell D, Chase DC, Goldman MH. Occult disease in tissue and organ donors. Transplantation 1994; 58: 734-738.
27. Houyel L, Petit J, Nottin R, Duffet JP, Mace L, Neveux JY. Adults heart transplantation: adverse role of chronic alcoholism in donors on early graft function. J Heart Lung Transplant 1992; 11: 1.184-1.187.
28. Freimark D, Czer LS, Admon D, Aleksic I, Valenza M, Borath P et al. Donors with history of cocaine use: effect of survival and rejection frequency after heart transplantation. J. Heart Lung Transplant 1994; 13: 1.138-1.144.
29. Hantosin P et al. Outcome following organ removal from poisoned donors: experience with 12 cases and a review of the literature. Transplant Int 1995; 8: 185.
30. Puig M, Ris J. Infecciones transmisibles a través del trasplante de órganos y tejidos. En: El donante de órganos y tejidos. Evolución. Manejo. Barcelona: Spinger-Velag Ibérica, 1977; 251-283.
31. Fenta V et al. Electrocardiographic patterns in patients with cerebrovascular accidents. Circulation 1962; 25: 22.
32. Gilbert EM, Krueger SK, Murray JL, Renlund DG, O'Connell JB, Gay WA et al. Echocardiographic evaluation of potencial cardiac transplant donors. Thorac Cardiovasc Surg 1988; 95: 1.003-1.007.
33. Trasplante cardíaco. En: Trasplantes torácicos. Madrid: Organización Nacional de Trasplantes (ONT). 1998.
34. Nossal GJV. The basic components of the immune system. N Engl J Med 1987; 316: 1.320-1.326.
35. Valantine HA. Individualizing immunosuppression for heart transplantation: strategies for the next decade. Transplant Proc 1997; 29: 5S-8S.
36. Nair RV, Morris RE. Immunosuppression in cardiac transplantation: a new era in immunopharmacology. Curr Opinion Cardiol 1995; 10: 207-217.
37. Bieber CP. Pharmacokinetics of antithymocyte globulin and cardiac transplant outcome. J Heart Transplant 1982; 1: 22-26.
38. O'Connell JB, Renlund DG, Gay WA et al. Efficacy of OKT3 retreatment for refractory cardiac allograft rejection. Transplantation 1988; 47: 788-792.
39. Costanzo-Nordin MR. Immunosupression in organ transplantation. Trasplantology 1993; 4: 14-26.
40. Kalian BD. Cyclosporine. N Engl J Med 1989; 321: 1.725-1.738.
41. Reichart B, Meiser B, Vigano M, Rinaldi M, Martinelli L, Yacoub M et al. European Multicenter Tacrolimus (FK506) Heart Pilot Study: one-year results-European Tacrolimus Multicenter Heart Study Group. J Heart Lung Transplant 1998; 17: 775-781.
42. Meiser BM, Uberfuhr P, Fuchs A, Schmidt D, Pfeiffer M, Paulus D et al. Single-center randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of acute myocardial rejection. J Heart Lung Transplant 1998; 17: 782-788.
43. Taylor DO. The use of tacrolimus and mycophenolate mofetil after cardiac transplantation. Curr Opinion Cardiol 1997; 12: 161-165.
44. Taylor DO, Ensley RD, Olsen SL, Dunn D, Renlund DG. Mycophenolate mofetil (RS-61443): preclinical, clinical, and three year experience in heart transplantation. J Heart Lung Transplant 1994; 13: 571-582.
45. Kobashigawa J, Miller L, Renlund D, Metzer R, Alderman E, Bourge R et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 1998; 66: 507-515.
46. Wahlers T. Cytolytic induction therapy in heart and lung transplantation: the protagonist opinion. Transplant Proc 1998; 30: 1.100-1.103.
47. Bristow MR, Gilbert EM, O'Conell JB, Renlund DG, Watson FS, Hammond E et al. Use of OKT3 monoclonal antibody in heart transplantation: review of the initial experience. Am J Kidney Dis 1998; 11: 135-140.
48. Kobashigawa JA. Treatment of nonhemodynamic compromising rejection: conventional approaches vs individualization/new immunosuppressive drugs. Transplant Proc 1997; 29: 37S-39S.
49. Hammond EH, Yowell RL, Nunoda S, Menlove RL, Renlund DG, Bristow MR et al. Vascular (humoral) rejection in heart transplantation: Pathologic observations and clinical implications. J Heart Transplant 1989; 8: 430-443.
50. Kirklin JK, Bourge RC, McGiffin DC. Recurrent or persistent cardiac allograft rejection: therapeutic options and recommendations. Transplant Proc 1997; 29: 40S-44S.
51. Billingham M, Cary N, Hammond E., Kemnitz J, Marboe C, McCallister HA et al. A working formulation for the standardisation of nomenclature in the diagnosis of heart and lung rejection: heart rejection study group. J Heart Transplant 1990; 9: 587-593.
52. Costanzo MR, Naftel DC, Pritzker MR, Heilman JK, Boehmer JP, Brozena SP et al. Heart transplant coronary artery disease detected by angiography: a multi-institutional study [resumen]. J Heart Lung Transplant 1998; 17:744-753.
53. Akosah KO, Mohanty PK, Funai JT, Jesse RL, Minisi AJ, Crandall CW et al. Noninvasive detection of transplant artery disease by dobutamine stress echocardiography. J Heart Lung Transplant 1994; 13: 1.024-1.038.
54. Spes CH, Mudra H, Schnaack SD, Klauss V, Reschle FM, Uberfuhr P et al. Dobutamine stress echocardiography for noninvasive diagnosis of cardiac allograft vasculopathy: a comparison with angiography and intravascular ultrasound. Am J Cardiol 1996; 78: 168-174.
55. Gao SZ, Alderman EL, Schroeder JS, Silverman JF, Hunt SA. Accelerated coronary vascular disease in the heart transplant patient: coronary arteriographic findings. J Am Coll Cardiol 1988; 12: 334-340.
56. Mehra MR, Ventura HO, Stapleton DD, Smart FW, Collins TC, Ramee SR. Presence of severe intimal thickening by intravascular ultrasonography predicts cardiac events in cardiac allograft vasculopathy. J Heart Lung Transplant 1995; 14: 632-639.
57. Rickenbacher PR, Pinto FJ, Lewis NP, Hunt SA, Alderman EL, Schroeder JS et al. Prognostic importance of intimal thickness as measured by intracoronary ultrasound after cardiac transplantation. Circulation 1995; 92: 3.445-3.452.
58. Liang DH, Gao SZ, Botas J, Pinto FJ, Schroeder JS, Alderman EL et al. Prediction of angiographic disease by intracoronary ultrasonographic findings in heart transplant recipients. J Heart Lung Transplant 1996; 15: 980-987.
59. Organ Procurement and Transplant Network. Final Rule. Department of Health and Human Services of Health Resources and Services Administration. Federal Register: April 2, 1998 (Vol 63, N. 63).
60. Report of Task Force on Organ Transplantation. Organ Transplants. Issues and Recommendations. U.S. Department of Health and Human Services. Public Health Services. Resources and Services. Washington D.C. April 1996.
61. Ley 30/1979, de 27 de Octubre, sobre Extracción y Trasplante de Órganos. Bolet ín Oficial del Estado. número 266. de 6 de noviembre de 1979.
62. Real Decreto 426/1980. de 22 de febrero, por el que se desarrolla la Ley 30/1979 sobre Extracción y Trasplante de Órganos. Boletín Oficial del Estado. número 63, de 13 de marzo de 1980.
63. País Vasco. Orden de 16 de octubre de 1990, sobre autorización de centros sanitarios para la Extracción y Trasplante de Órganos y Tejidos. BOPV de 9 de noviembre de 1990.
64. Comunidad de Murcia. Orden de 20 de marzo de 1991, sobre autorización de centros sanitarios para la Extracción y Trasplante de Organos y Tejidos. BORM de 8 de abril de 1991.
65. Comunidad de Madrid. Orden 950/1992 de 15 de diciembre de 1992. sobre autorización de centros sanitarios para la Extracción y Trasplante de Órganos y Tejidos. BOOM de 14 de enero de 1993.
66. Principado de Asturias. Decreto 24/92 de 6 de marzo de 1992, sobre autorización de centros sanitarios para la Extracción y Trasplante de Órganos y Tejidos. BOPA de 13 abril de 1992.
67. Comunidad de Castilla-La Mancha. Orden de 12 de agosto de 1996, sobre autorización de centros sanitarios para la Extracción y Trasplante de Órganos y Tejidos. BOCM de 23 de agosto de 1996.
68. Generalitat de Catalunya. Orden de 16 de agosto de 1984. sobre autorización de centros sanitarios para la Extracción y Trasplante de Órganos Humanos. BOGC de 22 de agosto de 1984.
69. Generalidad de Valencia. Orden de 11 de diciembre de 1992, sobre autorización de centros sanitarios para la Extracción y Trasplante de Órganos y Tejidos. BOGV de 27 de enero de 1993.
70. Junta de Andalucía. Decreto 91/1992 de 26 de mayo, sobre el programa de detección, extracción y trasplante de órganos y tejidos. BOJA de 20 de junio de 1992.
71. Junta de Galicia. Orden de 10 de julio de 1987, sobre autorización de centros sanitarios para la Extracción y Trasplante de Órganos y Tejidos. BOG A de 23 de julio de 1987.
72. Memoria de Actividad de la Organización Nacional de Trasplantes. 1991-1998.
73. Medicare Program. Criteria for Medicare coverage of heart transplants. Health care financing adminitration. Federal register: April 6, 1987 (Vol 52, n.° 65).
74. Hunsicker LG, Edwars EB, Breen TJ, Daily OP. Effect of center size and patient-mix cavariates on transplant center specific patient and graft survival in the United States. Transpl Proc 1993; 25: 1.318-1.320.
75. Brudick J, Norman DJ, Hunsiker LG, Costanzo-Nordin M, Edwars E, Bollinger RR. Identification of poorly performing transplant centers using UNOS center-specific data. Transplant Proc 1997; 29: 1.459.